
Joseph R Testa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7803965/publications.pdf Version: 2024-02-01



LOSEDH P TESTA

#	Article	IF	CITATIONS
1	Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005, 24, 7455-7464.	5.9	1,184
2	Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics, 2011, 43, 1022-1025.	21.4	924
3	Molecular alterations of the <i>AKT</i> 2 oncogene in ovarian and breast carcinomas. International Journal of Cancer, 1995, 64, 280-285.	5.1	781
4	BAP1 and cancer. Nature Reviews Cancer, 2013, 13, 153-159.	28.4	522
5	Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E. Cancer Cell, 2010, 17, 249-261.	16.8	420
6	TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10397-10402.	7.1	280
7	Amplification and overexpression of theAKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis, 1998, 21, 81-86.	2.7	276
8	AKT signaling in normal and malignant cells. Oncogene, 2005, 24, 7391-7393.	5.9	252
9	Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet, The, 2001, 357, 444-445.	13.7	250
10	p21-activated Kinase Links Rac/Cdc42 Signaling to Merlin. Journal of Biological Chemistry, 2002, 277, 883-886.	3.4	236
11	Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8387-8392.	7.1	225
12	Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2007, 25, 2406-2413.	1.6	219
13	RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model. Clinical Cancer Research, 2007, 13, 4261-4270.	7.0	216
14	Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene, 1997, 15, 1043-1049.	5.9	213
15	Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis. Current Treatment Options in Oncology, 2008, 9, 147-157.	3.0	207
16	Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. Science Translational Medicine, 2014, 6, 237ra68.	12.4	203
17	Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene, 1999, 18, 4891-4898.	5.9	190
18	RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. Cancer Research, 2007, 67, 2408-2413.	0.9	178

#	Article	IF	CITATIONS
19	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes and Cancer, 1997, 20, 320-328.	2.8	169
20	Comprehensive Study of the Clinical Phenotype of Germline <i>BAP1</i> Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164
21	Diverse Mechanisms of AKT Pathway Activation in Human Malignancy. Current Cancer Drug Targets, 2013, 13, 234-244.	1.6	156
22	The <i>NF2</i> Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression. Molecular and Cellular Biology, 2005, 25, 2384-2394.	2.3	155
23	Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene, 2005, 24, 6080-6089.	5.9	153
24	A Mouse Model Recapitulating Molecular Features of Human Mesothelioma. Cancer Research, 2005, 65, 8090-8095.	0.9	152
25	mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. Clinical Cancer Research, 2009, 15, 5404-5413.	7.0	151
26	Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 2000, 19, 410-416.	5.9	142
27	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	16.8	141
28	Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene, 1997, 14, 2793-2801.	5.9	139
29	Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. Journal of Cellular Physiology, 1999, 180, 150-157.	4.1	139
30	APPL1 Associates with TrkA and GIPC1 and Is Required for Nerve Growth Factor-Mediated Signal Transduction. Molecular and Cellular Biology, 2006, 26, 8928-8941.	2.3	137
31	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood, 2012, 120, 3764-3773.	1.4	132
32	Frequent activation of AKT2 kinase in human pancreatic carcinomas. Journal of Cellular Biochemistry, 2002, 87, 470-476.	2.6	131
33	Germline Mutation of <i>Bap1</i> Accelerates Development of Asbestos-Induced Malignant Mesothelioma. Cancer Research, 2014, 74, 4388-4397.	0.9	129
34	GIPC Is Recruited by APPL to Peripheral TrkA Endosomes and Regulates TrkA Trafficking and Signaling. Molecular and Cellular Biology, 2006, 26, 8942-8952.	2.3	124
35	Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene, 1998, 16, 2407-2411.	5.9	118
36	Human Follicle-Stimulating Hormone (FSH) Receptor Interacts with the Adaptor Protein APPL1 in HEK 293 Cells: Potential Involvement of the PI3K Pathway in FSH Signaling1. Biology of Reproduction, 2004, 71, 629-636.	2.7	104

#	Article	IF	CITATIONS
37	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	8.5	104
38	Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes and Cancer, 2001, 31, 282-287.	2.8	101
39	Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism ofNF2 inactivation. Genes Chromosomes and Cancer, 1999, 24, 238-242.	2.8	97
40	Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline <i>Bap1</i> Mutations. Cancer Research, 2016, 76, 2836-2844.	0.9	95
41	Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Research, 2016, 76, 206-215.	0.9	93
42	Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. Oncogene, 1997, 14, 1973-1979.	5.9	92
43	Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes. Genes Chromosomes and Cancer, 1989, 1, 148-154.	2.8	91
44	The biology of ovarian cancer development. Cancer, 2010, 71, 530-536.	4.1	91
45	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	2.8	90
46	Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genetics, 2013, 206, 206-210.	0.4	81
47	Cancer stemâ€like cell properties are regulated by <scp>EGFR</scp> / <scp>AKT</scp> /β–catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS Journal, 2013, 280, 2027-2041.	4.7	81
48	FAS-Associated Factor 1 (FAF1): Diverse functions and implications for oncogenesis. Cell Cycle, 2009, 8, 2528-2534.	2.6	80
49	Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics, 2010, 9, 2411-2422.	4.1	76
50	Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Annals of the New York Academy of Sciences, 2010, 1203, 7-14.	3.8	74
51	Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chromosomes and Cancer, 1994, 11, 178-194.	2.8	72
52	Activated TNF-α/NF-κB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from <i>Arf</i> knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3420-3425.	7.1	69
53	Inflammation-Related IL1 ^{î2} /IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. Cancer Prevention Research, 2016, 9, 406-414.	1.5	68
54	Genomic events associated with progression of pleural malignant mesothelioma. International Journal of Cancer, 2009, 124, 589-599.	5.1	67

#	Article	IF	CITATIONS
55	SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology, 2015, 10, 387-391.	1.1	67
56	Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes and Cancer, 2001, 30, 245-253.	2.8	65
57	Chromosome alterations in 21 non-small cell lung carcinomas. Genes Chromosomes and Cancer, 1990, 2, 328-338.	2.8	64
58	Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization. , 1997, 18, 115-125.		64
59	Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Molecular Cancer, 2010, 9, 314.	19.2	64
60	HGF Mediates Cell Proliferation of Human Mesothelioma Cells through a PI3K/MEK5/Fra-1 Pathway. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 209-217.	2.9	63
61	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Reports, 2018, 24, 3513-3527.e7.	6.4	61
62	Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis. PLoS ONE, 2011, 6, e18828.	2.5	59
63	Loss of GATA6 Leads to Nuclear Deformation and Aneuploidy in Ovarian Cancer. Molecular and Cellular Biology, 2009, 29, 4766-4777.	2.3	56
64	Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Cells via a p53–miR-34a–c-Met Axis. Cancer Research, 2014, 74, 1261-1271.	0.9	55
65	BAP1, a tumor suppressor gene driving malignant mesothelioma. Translational Lung Cancer Research, 2017, 6, 270-278.	2.8	54
66	NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. Modern Pathology, 2019, 32, 710-716.	5.5	54
67	Appl1 Is Dispensable for Mouse Development, and Loss of Appl1 Has Growth Factor-selective Effects on Akt Signaling in Murine Embryonic Fibroblasts. Journal of Biological Chemistry, 2010, 285, 6377-6389.	3.4	49
68	Upregulation of DLX5 Promotes Ovarian Cancer Cell Proliferation by Enhancing IRS-2-AKT Signaling. Cancer Research, 2010, 70, 9197-9206.	0.9	49
69	GSK690693 Delays Tumor Onset and Progression in Genetically Defined Mouse Models Expressing Activated Akt. Clinical Cancer Research, 2010, 16, 486-496.	7.0	49
70	A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes and Cancer, 2010, 1, 493-505.	1.9	48
71	The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genetics, 2015, 208, 206-214.	0.4	48
72	Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biology and Therapy, 2016, 17, 328-335.	3.4	47

#	Article	IF	CITATIONS
73	PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nature Communications, 2019, 10, 5800.	12.8	47
74	Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis, 2016, 37, 177-187.	2.8	44
75	Activated cAMP Response Element Binding Protein Is Overexpressed in Human Mesotheliomas and Inhibits Apoptosis. American Journal of Pathology, 2009, 175, 2197-2206.	3.8	43
76	Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf–MAPK Pathways. Molecular Cancer Research, 2012, 10, 1178-1188.	3.4	42
77	Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene–environment interaction. Cancer Letters, 2015, 369, 261-265.	7.2	42
78	Inactivation of <i>Bap1</i> Cooperates with Losses of <i>Nf2</i> and <i>Cdkn2a</i> to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models. Cancer Research, 2019, 79, 4113-4123.	0.9	42
79	DLX5 (Distal-less Homeobox 5) Promotes Tumor Cell Proliferation by Transcriptionally Regulating MYC. Journal of Biological Chemistry, 2009, 284, 20593-20601.	3.4	41
80	Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics, 2013, 12, 1367-1377.	4.1	41
81	BRCA1 Mutational Complementation Induces Synthetic Viability. Molecular Cell, 2020, 78, 951-959.e6.	9.7	41
82	Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. Journal of Cellular Biochemistry, 2002, 84, 455-459.	2.6	39
83	CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10456-10461.	7.1	39
84	ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. International Journal of Cancer, 2011, 129, 1075-1086.	5.1	38
85	Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes and Cancer, 1994, 9, 76-80.	2.8	37
86	High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2009, 48, 886-896.	2.8	37
87	Involvement of theRAFI locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes and Cancer, 1991, 3, 283-293.	2.8	36
88	A Novel Recurrent Chromosomal Inversion Implicates the Homeobox Gene <i>Dlx5</i> in T-Cell Lymphomas from Lck-Akt2 Transgenic Mice. Cancer Research, 2008, 68, 1296-1302.	0.9	31
89	Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplified DNA in a human lung carcinoma cell line. Genes Chromosomes and Cancer, 1997, 20, 208-212.	2.8	30
90	Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC Cancer, 2010, 10, 34.	2.6	29

#	Article	IF	CITATIONS
91	Translocation and activation of AKT2 in response to stimulation by insulin. Journal of Cellular Biochemistry, 1998, 70, 433-441.	2.6	28
92	Thymine DNA glycosylase as a novel target for melanoma. Oncogene, 2019, 38, 3710-3728.	5.9	28
93	Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes and Cancer, 2000, 28, 337-341.	2.8	27
94	A Novel Mechanism of Late Gene Silencing Drives SV40 Transformation of Human Mesothelial Cells. Cancer Research, 2008, 68, 9488-9496.	0.9	27
95	Identification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53. Journal of Biological Chemistry, 2012, 287, 11151-11163.	3.4	27
96	DLX Genes: Roles in Development and Cancer. Cancers, 2021, 13, 3005.	3.7	27
97	Constitutively Active Akt1 Cooperates with KRasG12D to Accelerate In Vivo Pancreatic Tumor Onset and Progression. Neoplasia, 2015, 17, 175-182.	5.3	26
98	Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing. Modern Pathology, 2019, 32, 1416-1420.	5.5	26
99	Somatic Epigenetic Silencing of <i>RIPK3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. Clinical Cancer Research, 2021, 27, 1200-1213.	7.0	26
100	Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells. Cancer Biology and Therapy, 2012, 13, 1082-1090.	3.4	25
101	Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. Molecular Cancer Research, 2015, 13, 795-806.	3.4	25
102	Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. ELife, 2018, 7, .	6.0	25
103	Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biology and Therapy, 2004, 3, 1313-1321.	3.4	24
104	Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. Cancer Research, 2016, 76, 3387-3396.	0.9	24
105	Familial and Somatic <i>BAP1</i> Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Research, 2018, 78, 1200-1213.	0.9	24
106	Clinical application of RNA sequencing in sarcoma diagnosis. Medicine (United States), 2019, 98, e16031.	1.0	24
107	A new human synovial sarcoma cell line, HS-SY-3, with a truncated form of hybridSYT/SSX1 gene. , 1999, 82, 459-464.		23
108	Combined classical cytogenetics and microarrayâ€based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes and Cancer, 2010, 49, 610-619.	2.8	22

#	Article	IF	CITATIONS
109	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer, 2015, 15, 376.	2.6	22
110	Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features. Journal of Urology, 2016, 195, 852-858.	0.4	22
111	Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene, 2001, 20, 6245-6249.	5.9	20
112	Whole-Genome Profiling in Liposarcomas Reveals Genetic Alterations Common to Specific Telomere Maintenance Mechanisms. Cancer Research, 2007, 67, 9221-9228.	0.9	20
113	Inactivation of <i>Tp53</i> and <i>Pten</i> drives rapid development of pleural and peritoneal malignant mesotheliomas. Journal of Cellular Physiology, 2018, 233, 8952-8961.	4.1	20
114	Akt1 and Akt2 Differently Regulate Muscle Creatine Kinase and Myogenin Gene Transcription in Insulin-Induced Differentiation of C2C12 Myoblasts. Endocrinology, 2002, 143, 820-828.	2.8	20
115	Factors that Impact Susceptibility to Fiber-Induced Health Effects. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2011, 14, 246-266.	6.5	19
116	Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0164554.	2.5	19
117	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS ONE, 2019, 14, e0222392.	2.5	19
118	Preclinical Models of Malignant Mesothelioma. Frontiers in Oncology, 2020, 10, 101.	2.8	19
119	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 81-90.	3.8	19
120	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7773-7778.	7.1	18
121	Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. , 1997, 74, 162-170.		17
122	NF-κB Inhibition by Bortezomib Permits IFN-γ–Activated RIP1 Kinase–Dependent Necrosis in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2013, 12, 1568-1578.	4.1	17
123	Challenging Global Waste Management – Bioremediation to Detoxify Asbestos. Frontiers in Environmental Science, 2020, 8, .	3.3	17
124	Cyclin T2A Gene Maps on Human Chromosome 2q21. Journal of Histochemistry and Cytochemistry, 2001, 49, 693-697.	2.5	16
125	Recurrent chromosomal rearrangements implicate oncogenes contributing to Tâ€cell lymphomagenesis in Lckâ€MyrAkt2 transgenic mice. Genes Chromosomes and Cancer, 2009, 48, 786-794.	2.8	16
126	Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer Biology and Therapy, 2015, 16, 580-588.	3.4	16

#	Article	IF	CITATIONS
127	Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 37423-37434.	1.8	16
128	Asbestos and Other Hazardous Fibrous Minerals: Potential Exposure Pathways and Associated Health Risks. International Journal of Environmental Research and Public Health, 2022, 19, 4031.	2.6	16
129	Appl1 is dispensable for Akt signaling in vivo and mouse Tâ€cell development. Genesis, 2010, 48, 531-539.	1.6	15
130	An Extracellular Signal–Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 906-914.	2.9	14
131	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 81-90.	3.8	14
132	Inhibition of mesothelioma cancer stemâ€like cells with adenovirusâ€mediated <scp>NK</scp> 4 gene therapy. International Journal of Cancer, 2015, 137, 481-490.	5.1	13
133	An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. Cancer Genetics, 2015, 208, 502-507.	0.4	13
134	Appl1andAppl2are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. Journal of Cellular Physiology, 2016, 231, 1142-1150.	4.1	13
135	Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leukemia Research Reports, 2012, 1, 4-6.	0.4	12
136	Molecular Cytogenetic Analysis of the Scleractinian Coral <i>Acropora solitaryensis</i> Veron & Wallace 1984. Zoological Science, 2014, 31, 89-94.	0.7	12
137	Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Genetics, 2014, 207, 98-102.	0.4	11
138	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for <i>VHL</i> or <i>TSC</i> mutation. Oncotarget, 2017, 8, 17628-17642.	1.8	11
139	The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling. Oncotarget, 2017, 8, 14941-14956.	1.8	9
140	Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma. Cancer Biology and Therapy, 2020, 21, 424-431.	3.4	8
141	Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. American Journal of Cancer Research, 2017, 7, 1724-1737.	1.4	8
142	Tumor suppressor genes and the two-hit model of recessive oncogenesis: Celebrating Alfred Knudson's 80th birthday. Genes Chromosomes and Cancer, 2003, 38, 286-287.	2.8	7
143	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. Molecular Cancer Therapeutics, 2020, 19, 2221-2232.	4.1	7
144	Novel <i>LRRK2</i> mutations and other rare, non- <i>BAP1</i> related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Human Molecular Genetics, 2021, 30, 1750-1761.	2.9	7

#	Article	IF	CITATIONS
145	Cytogenetic abnormalities in non-small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures. Genes Chromosomes and Cancer, 1993, 6, 30-38.	2.8	6
146	Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis. Scientific Reports, 2020, 10, 15837.	3.3	6
147	Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of <i>Nf2</i> -Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling. Molecular Cancer Research, 2022, 20, 699-711.	3.4	6
148	Absence of post-transcriptional RNA modifications ofBCL10 in human malignant mesothelioma and colorectal cancer. Genes Chromosomes and Cancer, 2001, 30, 96-98.	2.8	5
149	Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia. Leukemia Research Reports, 2016, 5, 23-26.	0.4	5
150	Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-grade Renal Cell Carcinoma With Clear Cell and Papillary Features. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 123-129.	1.2	4
151	Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 56-61.	1.9	4
152	Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability. Cancers, 2022, 14, 3108.	3.7	4
153	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 3-10.	2.0	3
154	Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models. Current Cancer Research, 2017, , 175-195.	0.2	3
155	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes and Cancer, 1997, 20, 320-328.	2.8	2
156	Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis, 1998, 21, 81-86.	2.7	2
157	Malignant Mesothelioma: An Asbestos Legacy. Current Cancer Research, 2017, , 1-9.	0.2	1
158	Malignant Mesothelioma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	1
159	Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. Molecular Cancer Research, 2021, 19, 1099-1112.	3.4	1
160	Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. , 2000, 28, 337.		1
161	SV40 infection induces telomerase activity in human mesothelial cells. , 0, .		1